Antagonistic and Immunomodulant Effects of Two Probiotic Strains of Lactobacillus on Clinical Strains of Helicobacter pylori
AbstractBackground: The present study aimed to evaluate the in vitro and in situ antagonistic effects of Lactobacillus probiotic strains on clinical strains of Helicobacter pylori . Also to investigate their immunomodulation effects on a macrophage cell model. Materials and Methods: Anti-microbial effects of probiotic lactobacilli against H. pylori was assessed using the well and disk diffusion methods. Effects of lactobacilli probiotics strains, as well as their cell-free supernatant on adhesion of H. pylori to MKN-45 gastric epithelial cells, were examined in their presence and absence. Immunomodulation effects of probiotic lactobacilli were performed using the U937 macrophage cell model. Incubation of host cells with probiotics and their cell-free supernatants with cultured host cells was performed in different optimized conditions. The supernatant of host cells cultured in their presence and absence was used for cytokines measurement. Results: Two probiotics, Lactobacillus acidophilus ATCC4356, and Lactobacillus rhamnosus PTCC1607, could inhibit the growth of clinical H. pylori in vitro. They could also inhibit attachment of H. pylori to MKN-45 cells. Cell-free supernatant of L. acidophilus had a stimulating effect on the production of Interferon-gamma (IFN-γ) by U937 cells. Conclusion: The present study demonstrates that, L. acidophilus ATCC4356 and L. rhamnosus PTCC1607 probiotic strains can inhibit the growth of clinical H. pylori in vitro. Treatment of U937 with alive H. pylori plus cell-free supernatant of L. acidophilus, have a significantly higher capacity to stimulate IFN-γ production than H. pylori alone. So, the metabolite (s) of this probiotic may have an immunomodulatory effect in immune response versus H. pylori. [GMJ.2020;9:e1794]
Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002; 347:1175-1186.
Lopes D, Nunes C, Martins MCL, Sarmento B, Reis S. Eradication of Helicobacter pylori: past, present and future. J Control Release. 2014;189:169-186.
Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, Fukuda K, Fujita Y, Katsurahara M, Ito T, Cesar GE, Imoto I, Takei Y. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter. 2009;14:86-90.
Megraud F, Coenen S, Versporten A, Kist M, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Study Group participants Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34-42.
Go MF. Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002;16 Suppl. 1:3-15.
Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587.
Amedei A, Cappon A, Codolo G, Cabrelle A, Polenghi A, Benagiano M, Tasca E, Azzurri , D'Elios MM, Del Prete G, Bernard M. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest. 2006;116:1092-1101.
Emara MH, Mohamed SY, Abdel-Aziz HR. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients:a double-blind placebo-controlled randomized clinical trial. Therap Adv Gastroenterol. 2014;7:4-13.
Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Des. 2003;9:175-191.
Vrese MD, Schrezenmei J. Probiotics and non-intestinal infectious conditions. Br J Nutr. 2002;88 Suppl 1:59-66.
Habermann W, Zimmermann K, Skarabis H, Kunze R, Rusch V. Reduction of acute relapses in patients with chronic recurrent hypertrophic sinusitis during treatment with a bacterial immunostimulant (Enterococus faecalis bacteria of human origin*/a medical probiotic). Arzneimittel Forschung. 2002;52:622_7.
Moal VL, Servin AL. Anti-Infective Activities of Lactobacillus Strains in the Human Intestinal Microbiota: from Probiotics to Gastrointestinal Anti- Infectious Biotherapeutic Agents. Clin. Microbiol. Rev. Clinical Microbiology Reviews. 2014;27(2):167-199.
Yang YJ, Chuang CC, Yang HB, Lu CC, Sheu BS. Lactobacillus acidophilus ameliorates H.pylori induced gastric inflammation by inactivating the Smad7 and NF-B pathways. BMC Microbiology. 2012;12:38.
Wittig BM, Zeitz M. The gut as an organ of immunology. Int J Colorectal Dis. 2003;18:181-187.
Vaarala O. Immunological effects of probiotics with special reference to lactobacilli. Clin Exp Allergy. 2003;33:1634-1640.
Maassen K. Lactobacilli as antigen delivery system for mucosal tolerance in autoimmune disease. PhD thesis. Erasmus University of Rotterdam, the Netherlands. 1999.
Miettinen, M, Matikainen S, Vuopio-Varkila J, Pirhonen J, Varkila K, Kurimoto M, Julkunen I. Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Infect. Immun. 1998;66:6058-6062.
Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680.
Panpetch W, Thiraworawong T, Tumwasorn S. Human gastric biopsy-derived lactobacilli suppress Helicobacter pylori-induced interleukin-8 production from gastric epithelial cells in vitro. Int J Infereron Cytokine Mediator Res. 2011;3:43-49.
Klerk N, Maudsdotter L, Gebreegziabher H, Saroj SD, Eriksson B, Eriksson OS, Roos S, Linden S, Sjӧlinder H, Jonsson A. Lactobacilli Reduce Helicobacter pylori Attachment to Host Gastric Epithelial Cells by Inhibiting Adhesion Gene Expression. Infect Immun. 2016;84:1526-1535.
Bhatia SJ, Kochar N, Abraham P, Nair NG, Mehta AP. Lactobacillus acidophilus irihibits growth of Campylobacter pylori in-vitro. Clin Microbiol Rev. 1989;27:2328-2330.
Michetti P, Dorta G, Wiesel PH, Brassart D, Verdu E, Herranz M, Felley C, Porta N. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion. 1999;60:203-209.
Oconnor A, Vaira D, Gisbert JP, Morain C. Treatment of Helicobacter pylori infection 2014. Helicobacter. 2014;19 suppl 1:38-45.
Kabir AM, Aiba Y, Takagi A, Kamiya S, Miwa T, Koga Y. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut. 1997;41:49-55.
Ryan KA, Daly P, Li Y, Hooton C, O'Toole PW. Strain-specific inhibition of Helicobacter pylori by Lactobacillus salivarius and other lactobacilli. J Antimicrob Chemother. 2008;61:831-834.
Bamford KB, Fan X, Crowe SE, Leary JF, Gourley WK, Luthra GK, Brooks EG, Graham DY, Reyes VE, Ernst PB. Lymphocytes in the human gastric mucosa during Helicobacter pylori infection have a T helper cell 1 phenotype. Gastroenterology. 1998;114:482-492.
Haeberle HA, Kubin M, Bamford KB, Garofalo R, Graham DY, El-Zaatari F, Karttunen R, Crowe SE, Reyes VE, Ernst PB. Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa. Infect Immun. 1997;65:4229-4235.
Karttunen R, Karttunen T, Ekre HP, MacDonald TT. Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut. 1995;36:341-345.
Lindholm C, Quiding-Jarbrink M, Lonroth H, Hamlet A, A. Svennerholm M. Local cytokine response in Helicobacter pylori-infected subjects. Infect Immun. 1998;66:5964-5971.
Sommer F, Faller G, Konturek P, Kirchner T, Hahn EG, Zeus J, Rollinghoff M, Lohoff M. Antrum- and corpus mucosa-infiltrating CD4_ lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype. Infect Immun. 1998;66:5543-5546.
Gobert AP, Bambou JC, Werts C, Balloy V, Chignard M, Moran AP, Ferrero RL. Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a Toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism. J Biol Chem. 2004;279:245-250.
Harris PR, Ernst PB, Kawabata S, Kiyono H, Graham MF, Smith PD. Recombinant Helicobacter pylori urease activates primary mucosal macrophages. J Infect Dis. 1998;178:1516-1520.
Mai UE, Perez-Perez GI, Wahl LM, Wahl SM, Blaser MJ, Smith PD. Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism. J Clin Investig. 1991;87:894-900.
Basu M, Czinn SJ, Blanchard TG. Absence of catalase reduces long-term survival of Helicobacter pylori in macrophage phagosomes. Helicobacter. 2004;9:211-216.
Gobert AP, McGee DJ, Akhtar M, Mendz GL, Newton JC, Cheng Y, Mobley HL, Wilson KT. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. Proc Natl Acad Sci USA. 2001;98:13844-13849.
Chaturvedi R, Cheng Y, Asim M, Bussiere FI, Xu H, Gobert AP, Hacker A, Casero RA, Wilson KT. Induction of polyamine oxidase 1 by Helicobacter pylori causes macrophage apoptosis by hydrogen peroxide release and mitochondrial membrane depolarization. J Biol Chem. 2004;279:40161-40173.
Cheng Y, Chaturvedi R, Asim M, Bussiere FI, XuH, CaseroRA, Wilson Jr, KT Wilson. Helicobacter pylori-induced macrophage apoptosis requires activation of ornithine decarboxylase by c-Myc. J Biol Chem. 2005;280:22492-22496.
Gobert AP, Cheng Y, Wang JY, Boucher JL, Iyer RK, Cederbaum SD, Casero RA, Newton JC, and KT Wilson. Helicobacter pylori induces macrophage apoptosis by activation of arginase II. J Immunol. 2002;168:4692-4700.
Miettinen M, Matikainen S, Vuopio-Varkila J, Pirhonen J, Varkila K, Kurimoto M, Julkunen I. Lactobacilli and Streptococci Induce Interleukin-12 (IL-12), IL-18, and Gamma Interferon Production in Human Peripheral Blood Mononuclear Cells. Infect Immun. 1998;66:6058-6062.
Trinchieri G. Interleukin-12 and the regulation of innate resistance and adoptive immunity. Nat. Rev Immunol. 2003;3:133-146.
Maassen CB, van Holten-Neelen C, Balk F, den Bak-Glashouwer MJ, Leer RJ, Laman JD, Boersma WJ, Claassen E. Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine. 2000;18:2613-2623.
Trapp CL, Chang CC, Halpern GM. The influence of chronic yogurt consumption on populations of young and elderly adults. Int J Immunother. 1993;9:53-64.
Yang YJ, Sheu BS. Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter. 2012;17:297-304.
Solis Pereyra B, Lemonnier D. Induction of human cytokines by bacteria used in dairy foods. Nutr Res Rev. 1993;13:1127-1140.
Solis Pereyra B, Aattouri N, Lemonnier D. Role of food in the stimulation of cytokine production. Am J Clin Nutr. 1997;66:521S-525S.
Miettinen M, Vuopio-Varkila J, Varkila K. Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun. 1996;64:5403-5405.
Aiba Y, Suzuki N, Kabir AM, Takagi A, Koda Y. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murin model. Am J Gastroenterol. 1998;93:2097-2101.
Coconnier MH, Lievin V, Hemery E, and Servin AL. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol. 1998;64:4573-4580.
Michetti P, Dorta G, Brassart D, Vouillamoz D, Schwitzer W, Felley C, Blum AL, Porta N, Rouvet M, Corthesy-Theulaz I. Lactobacillus acidophilus supernatant as an adjuvant in the therapy of H.pylori in humans. Gastroenterology. 1995;108:A166.
Kitazawa H, Matsumura K, Itoh T, Yamaguchi T.: Interferon induction in murine peritoneal macrophage by stimulation with Lactobacillus acidophilus. Microbiol Immunol. 1992;36:311-315.
De Simone C, Vesely R, Bianchi Salvadori B, Jirillo E. The role of probiotics in modulation of the immune system in man and in animals. Int J Immunotherapy. 1993;9:23-28.
Pereyra, BS, Lemonnier D. Induction of human cytokines by bacteria used in dairy foods. Nutr Res. 1993;13:1127-1140.
Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E, Mentis A. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol. 2004;70:518-526.
Lin WH, Wu CR, Fang TJ, Guo JT, Huang SY, Lee MS, Yang HL. Anti-Helicobacter pylori activity of fermented milk with lactic acid bacteria. J Sci Food Agric. 2011;91:1424-1431.
Aiba Y, Suzuki N, Kabir AM, Takagi A, Koga Y. Lactic acidmediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol. 1998;93:2097-210.
Ljungh A, Wadström T. Lactic acid bacteria as probiotics. Curr Issues Intest Microbiol. 2006;7:73-89.
Konstantinov SR, Smidt H, de Vos WM, Bruijns SC, Singh, SK, Valence F, Molle D, Lortal S, Altermann E, Klaenhammer TR, van Kooyk Y. S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. PNS USA. 2008;105:19474-19479.
Cotter PD, Ross RP, Hill C. Bacteriocins-aviable alternative to antibiotics? Nat Rev Microbiol. 2013;11:95-105.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).